首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1374780

全球脑脊髓液管理市场 -2023-2030

Global Cerebrospinal Fluid Management Market -2023-2030

出版日期: 2023年11月01日 | 出版商:

DataM Intelligence | 英文 187 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

多年来，全球脑脊髓液管理市场经历了显着的成长和变革，影响其动态的因素有很多。中枢神经系统的稳态主要由脑脊髓液 (CSF) 维持。脑脊髓液 (CSF) 的管理需要使用分流器或外部引流系统等工具来维持脑脊髓液流动。

政府新产品的推出和研究，特别是在发展中经济体，将继续推动先进脑脊髓液（CSF）分流器或外部引流系统的利用，并推动全球脑脊髓液管理市场。各自的创新产品可用于不同年龄层的人。

市场动态：驱动因素与限制因素

不断增长的合作和收购

在高投资、收入水准和基础设施发展的推动下，已开发经济体的医疗保健产业不断改善。由于研究的不断增加，一些国家对脑脊髓液管理产生了巨大的需求。不同国家之间的各种合作、收购和技术进步的产品发布将是推动市场成长的关键因素。

2023 年 6 月 27 日，着名医疗器材公司和神经外科极其专业的设备或耗材製造商 Spiegelberg GmbH & Co. KG (Spiegelberg) 被瑞士医疗保健公司 Luciole Medical AG 收购。来自 SHS Capital 的大脑监测。收购后，两家公司将合併其产品线、生产能力和分销网络，以最大限度地发挥各自的优势，目标是成为尖端下一代脑监测设备开发的领导者。

此外，2023 年 6 月 26 日，LianMedical（一家专注于加速将突破性医疗技术引入亚洲市场的医疗器材製造商）和 CereVasc, Inc.（一家临床阶段的医疗器材公司，开发神经系统新疗法）疾病，联手将CereVasc 的eShunt 系统及相关产品带给中国、台湾、香港和澳门的消费者和医疗保健专业人员。

此外，越来越多地利用新技术和不同类型的脑脊髓液管理系统来进行治疗或多种研究目的。脑液漏的增加和创新管理产品开发研究的增加将是推动脑脊髓液管理市场成长的主要因素。

与分流术相关的併发症

儘管外科手术和抗生素预防有所改进，但感染仍然是分流术最严重的副作用。因此，用于分流器和 EVD 的抗菌生物材料已经诞生。了解这些问题的外科、生物材料和微生物成分对于此类设备的实验室评估是必要的。

最常见的是，一些与皮肤菌丛相关的低毒力微生物是脑脊髓液分流感染的原因。在大约 50% 至 80% 的分流感染中，凝固酶阴性和凝固酶阳性葡萄球菌被证明是常见的病原体。

The global cerebrospinal fluid management market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The central nervous system's homeostasis is crucially maintained by cerebrospinal fluid (CSF). The management of cerebral spinal fluid (CSF) entails the use of tools like shunts or external drainage systems to keep the CSF flowing.

Government novel product launch and research, particularly in developing economies, will continue to drive utilization of advanced cerebrospinal fluid (CSF) shunt or external drainage systems and boost the global cerebrospinal fluid management market. The respective innovative products are may be utilized in people with different age groups.

Market Dynamics: Drivers & Restraints

Growing collaborations and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for cerebrospinal fluid management owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On June 27, 2023, the Spiegelberg GmbH & Co. KG (Spiegelberg), a well-known medical device firm and manufacturer of extremely specialized devices or consumables for neurosurgery, was bought by Luciole Medical AG, a Swiss health care company with a focus on brain monitoring, from SHS Capital. After the acquisition, the businesses will merge their product lines, production capabilities, and distribution networks to maximize their strengths with the goal of emerging as a leader in the development of cutting-edge next-generation brain monitoring devices.

Additionally, on June 26, 2023, LianMedical, a manufacturer of medical devices focused on speeding up the introduction of ground-breaking medical technologies to markets in Asia, and CereVasc, Inc., a clinical-stage medical device business developing new therapies for neurological diseases, joined forces to bring CereVasc's eShunt System along with associated products to consumers and healthcare professionals in China, Taiwan, Hong Kong, and Macau.

Furthermore, the rising utilization of novel technology and different types of cerebrospinal fluid management systems for the treatment or several research purposes. Rising cerebral fluid leak and increasing research for innovative management product development will be a major factor driving the growth of the cerebrospinal fluid management market.

Complications associated with the shunts

Despite improvements in surgical procedures and antibiotic prophylaxis, infection is still the most severe side effect of shunts. As a result, antimicrobial biomaterials for shunts and EVDs have been created. Understanding the surgical, biomaterials, and microbiological components of the issues is necessary for the laboratory assessment of such devices.

Most frequently, some skin flora-associated low-virulence organisms are responsible for CSF shunt infections. In approximately 50% to 80% of the shunt infections, coagulase-negative and coagulase-positive staphylococci were shown to be the common causative agents.

Segment Analysis

The global cerebrospinal fluid management market is segmented based on product type, age group, end user and region.

Cerebrospinal Fluid (CSF) Shunt segment accounted for approximately 56% of market share

Shunts of cerebrospinal fluid are employed to treat hydrocephalus, which is brought on by increased pressure inside the brain. They are meant to be permanent fixtures. External ventricular drainage (EVD), which is utilized for sudden increases in pressure such those brought on by trauma or hemorrhage, is a more transient solution. Patients have CSF shunts implanted to drain fluid from their cysts, ventricles, and subdural deposits to organs that can absorb it, including the peritoneum or atrium.

The most frequent neurosurgical procedure carried out in the US is the insertion of CSF shunts. For existing or probable hydrocephalus/fluid space collections caused by spina bifida or intraventricular hemorrhage, shunts are most frequently implanted in young patients, and they have reduced mortality from these disorders.

On February 10, 2021, the first patient in a study of CereVasc, Inc.'s eShunt System, an investigational device aimed at treating communicating hydrocephalus (CH), which is among the most prevalent neurological conditions in the world, has been treated. CereVasc, Inc. is a clinical-stage medical equipment company creating novel, minimally invasive therapies for neurological diseases. The eShunt device, the first modern minimally invasive procedure for CH, has the potential to provide considerable advantages over the standard of care, a 50-year-old neurosurgical operation marked by frequent failure, an increased risk of infection, and high costs.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for cerebrospinal fluid management in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for cerebrospinal fluid management.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of products, and increase in biopharmaceutical or medical device business establishment across the region are also contributing to the growth of cerebrospinal fluid management market share of this region. The market in this area is growing as people become more aware of various novel innovative products such as cerebrospinal fluid (csf) shunt. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global cerebrospinal fluid management market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for cerebrospinal fluid management in the U.S. United States have been proactive in executing several initiatives or researches, stimulating cerebrospinal fluid management demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global cerebrospinal fluid management market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for cerebrospinal fluid management. Now several research studies have been initiated and companies have again started launching novel products with high efficiency. Overall, the impact of the pandemic on the global cerebrospinal fluid management market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for innovative products, like external drainage system.

Key Developments

On July 6, 2023, the External Ventricular Drain (EVD) catheter set, Codman Bactiseal is used to treat patients who have hydrocephalus as a side effect of aneurysmal subarachnoid hemorrhage (aSAH), according to positive clinical and financial results stated by Integra LifeSciences Holdings Corporation, an established global medical technology company.
On April 8, 2022, the VentrEX Complete is the ideal option for lumbar or ventricular drainage because it includes the VentrEX EVD System with a disposable stand. Its extensive range of intelligent functions, properly labeled parts, and easy-to-read scale ensure simple handling with the highest level of safety.

Competitive Landscape

The major global players in the market include: Medtronic, Integra LifeSciences, DePuy Synthes (Johnson & Johnson MedTech), B. Braun SE, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Neuromedex GmbH, MOLLER Medical GmbH, Argi Grup and Wellong Instruments Co., Ltd.

Why Purchase the Report?

To visualize the global cerebrospinal fluid management market segmentation based on product type, age group, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of cerebrospinal fluid management market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global cerebrospinal fluid management market report would provide approximately 61 tables, 56 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Age Group
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing collaborations and acquisitions
  - 4.1.1.2. Rising technological advancements and developments
- 4.1.2. Restraints
  - 4.1.2.1. Complications associated with the shunts
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Cerebrospinal Fluid (CSF) Shunt*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Ventriculoperitoneal (VP) Shunt
- 7.2.4. Ventriculopleural (VPL) Shunt
- 7.2.5. Ventriculoatrial (VA) Shunt
7.3. External Drainage System
- 7.3.1. External Ventricular Drainage (EVD)
- 7.3.2. Lumbar Drainage
- 7.3.3. Cisternal Drainage

8. By Age Group

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 8.1.2. Market Attractiveness Index, By Age Group
8.2. Pediatric *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adult
8.4. Geriatric

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Geriatric

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Medtronic*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Integra LifeSciences
12.3. DePuy Synthes (Johnson & Johnson MedTech)
12.4. B. Braun SE
12.5. Natus Medical Incorporated
12.6. Spiegelberg GmbH & Co. KG
12.7. Neuromedex GmbH
12.8. MOLLER Medical GmbH
12.9. Argi Grup
12.10. Wellong Instruments Co., Ltd.

LIST NOT EXHAUSTIVE